Atea Pharmaceuticals, Inc. — Director's Dealing 2020

Oct 30, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2020-10-29

Reporting Person: BERGER FRANKLIN M (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	18747	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Convertible Preferred Stock	$		Common Stock (400000)		Direct
Series B Convertible Preferred Stock	$		Common Stock (132014)		Direct
Series C Convertible Preferred Stock	$		Common Stock (131578)		Direct
Series D Convertible Preferred Stock	$		Common Stock (60540)		Direct
Series D-1 Convertible Preferred Stock	$		Common Stock (35474)		Direct
Stock Option (Right to Buy)	$1.43	2029-09-29	Common Stock (31253)		Direct

Footnotes

F1: Each share of Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

F2: The option vests as to 50,000 shares in 24 monthly installments following August 31, 2019.